000 05026nam a22003975i 4500
999 _c391953
_d391953
001 391953
003 ES-MaUEC
005 20230622131237.0
006 a|||| o|||| 00| 0
007 cr nn 008mamaa
008 230622s2006 xxu| o |||| 0|eng d
020 _a9781597450171
024 7 _a10.1385/1597450170
_2doi
040 _aES-MaUEC
_bspa
_cES-MaUEC
_dES-MaUEC
050 4 _aRC643
_b2006 EB
245 0 0 _aMyeloid Leukemia :
_bMethods and Protocols
_cedited by Harry Iland, Mark Hertzberg, Paula Marlton
250 _a1st edition 2006
264 1 _aTotowa, NJ
_bHumana Press
_c2006
300 _a1 recurso en línea (320 páginas)
_b69 ilustraciones
336 _atexto
_btxt
_2rdacontent
337 _aelectrónico
_bc
_2rdamedia
338 _arecurso electrónico
_bcr
_2rdacarrier
347 _aarchivo de texto
_bPDF
490 0 _aMethods in Molecular Medicine
_x1940-6037
_v125
505 0 _aIsolation of RNA and DNA From Leukocytes and cDNA Synthesis -- Cytogenetic and FISH Techniques in Myeloid Malignancies -- Overview of Real-Time RT-PCR Strategies for Quantification of Gene Rearrangements in the Myeloid Malignancies -- Diagnosis and Monitoring of Chronic Myeloid Leukemia by Qualitative and Quantitative RT-PCR -- Detection of BCR-ABL Mutations and Resistance to Imatinib Mesylate -- Deletion of the Derivative Chromosome 9 in Chronic Myeloid Leukemia -- Diagnosis and Monitoring of PML-RARA-Positive Acute Promyelocytic Leukemia by Qualitative RT-PCR -- Diagnosis and Monitoring of PML-RAR?-Positive Acute Promyelocytic Leukemia by Quantitative RT-PCR -- Diagnosis and Monitoring of AML1-MTG8 (ETO)-Positive Acute Myeloid Leukemia by Qualitative and Real-Time Quantitative RT-PCR -- Diagnosis and Monitoring of CBFB-MYH11-Positive Acute Myeloid Leukemia by Qualitative and Quantitative RT-PCR -- Detection of the FIP1L1-PDGFRA Fusion in Idiopathic Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia -- FLT3 Mutations in Acute Myeloid Leukemia -- WT-1 Overexpression in Acute Myeloid Leukemia and Myelodysplastic Syndromes -- Classification of AML by DNA-Oligonucleotide Microarrays -- Classification of AML Using a Monoclonal Antibody Microarray -- Methods for the Detection of the JAK2 V617F Mutation in Human Myeloproliferative Disorders -- Overexpression of PRV-1 Gene in Polycythemia Rubra Vera and Essential Thrombocythemia -- Chimerism Analysis Following Nonmyeloablative Stem Cell Transplantation.
520 _aThe highly significant role that acquired genetic abnormalities play in the genesis, diagnosis, and management of hematological malignancies has become increasingly clear. Such abnormalities can serve as useful markers for initial diagnosis, accurate subclassification, and the evaluation of minimal residual disease, as well as providing critical targets for novel therapies. In Myeloid Leukemia: Methods and Protocols, a panel of internationally recognized research scientists and clinical investigators brings together a diverse collection of readily reproducible methods for identifying and quantifying a large number of specific genetic abnormalities associated with the broad spectrum of myeloid malignancies. The methods range from those that are of immediate clinical relevance to the investigation and management of patients with myeloid malignancies, to those that relate to recently identified genetic abnormalities of potential clinical significance. Highlights include techniques for the detection of BCR-ABL mutations and resistance to imatinib mesylate, detection of the FIP1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia, classification of AML by DNA-oligonucleotide microarrays, and detection of the V617F JAK2 mutation in myeloproliferative disorders. In addition to gene rearrangments, other prognostically relevant molecular lesions such as FLT3 mutations and WT-1 overexpression are covered. The protocols follow the successful Methods in Molecular Biology™ series format, each offering step-by-step laboratory instructions, an introduction outlining the principles behind the technique, lists of the necessary equipment and reagents, and tips on troubleshooting and avoiding known pitfalls. Clinically relevant and highly practical, Myeloid Leukemia: Methods and Protocols offers cytogeneticists, hematologists, and oncologists cutting-edge laboratory techniques that can be rapidly implemented for the investigation and management of patients with myeloid malignancies.
988 _aSpringer_Protocols_2006
650 7 _2embne
_9676045
_aLeucemia mieloide crónica
776 0 8 _iPrinted edition:
_z9781607614562
776 0 8 _iPrinted edition:
_z9781607614579
776 0 8 _iPrinted edition:
_z9781588294852
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1385/1597450170
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942 _2lcc
_cLE
998 _b06/2023
_dz
_eIG
_zSI